These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31206565)

  • 1. Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.
    Schultz N; Janelidze S; Byman E; Minthon L; Nägga K; Hansson O; Wennström M
    PLoS One; 2019; 14(6):e0218561. PubMed ID: 31206565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
    Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
    Travassos M; Santana I; Baldeiras I; Tsolaki M; Gkatzima O; Sermin G; Yener GG; Simonsen A; Hasselbalch SG; Kapaki E; Mara B; Cunha RA; Agostinho P; Blennow K; Zetterberg H; Mendes VM; Manadas B; de Mendon A
    J Alzheimers Dis; 2015; 47(4):1069-78. PubMed ID: 26401784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
    Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
    J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.
    Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S
    Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
    Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.
    de Almeida SM; Ribeiro CE; Rotta I; Piovesan M; Tang B; Vaida F; Raboni SM; Letendre S; Potter M; Batistela Fernandes MS; Ellis RJ;
    J Neurovirol; 2018 Feb; 24(1):28-40. PubMed ID: 29063514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
    De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
    Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.